Multi-centre phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer. Yorkshire and Scottish Urological Cancer Research Groups.
作者信息
Whelan P, Cumming J A, Garvie W H, Hargreave T B, Kirk D, Newling D W, Robinson M R, Smith P H
机构信息
Department of Urology, St James's University Hospital, Leeds.
出版信息
Br J Urol. 1991 Jun;67(6):600-2. doi: 10.1111/j.1464-410x.1991.tb15223.x.
Abstract
Forty patients with multiple recurrent superficial bladder tumours received an 8-week course of weekly instillations of 4' epirubicin 30 mg in 50 ml saline. The overall response rate was 58% and side effects were minimal.
摘要
Zotero 插件